Fig. 3From: Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exerciseCost-effectiveness acceptability curve for dapagliflozin versus metformin. QALY quality-adjusted life year, ICER incremental cost-effectiveness ratioBack to article page